Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
76-90 of 118
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
MinuteCE®Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Applications of Emerging Data in Resectable NSCLC
MinuteCE®Applications of Emerging Data in Resectable NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
- advertisement
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
- advertisement
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
